Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate

Journal of the American Academy of Dermatology

Volumn 58, Issue 5 SUPPL. 1, 2008, Pages

  Steinhoff, Matthias ^a   Beyer, Marc ^a   Roewert Huber, Joachim ^a   Lukowsky, Ansgar ^a   Assaf, Chalid ^a   Sterry, Wolfram ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CLINDAMYCIN; FENOFIBRATE; VORINOSTAT;

ADULT; ARTICLE; BACTERIAL INFECTION; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; GRANULOMATOUS INFLAMMATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LOW DRUG DOSE; MALE; MYCOSIS FUNGOIDES; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUNCH BIOPSY; SKIN NECROSIS; SKIN SURGERY; TREATMENT OUTCOME; VEIN THROMBOSIS; WHOLE BODY CT;

ACUTE DISEASE; ANTICARCINOGENIC AGENTS; ANTILIPEMIC AGENTS; BIOPSY; DRUG ERUPTIONS; FEMALE; FEVER; GRANULOMA; HUMANS; HYDROXAMIC ACIDS; MIDDLE AGED; MYCOSIS FUNGOIDES; NECROSIS; PROCETOFEN; REMISSION INDUCTION; SKIN; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES;

EID: 41849085137     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.07.012     Document Type: Article

References (15)

1. Ackerman A.B., and Flaxman B.A. Granulomatous mycosis fungoides. Br J Dermatol 82 (1970) 397-401
2. Scarabello A., Leinweber B., Ardigo M., Rutten A., Feller A.C., Kerl H., et al. Cutaneous lymphomas with prominent granulomatous reaction: a potential pitfall in the histopathologic diagnosis of cutaneous T- and B-cell lymphomas. Am J Surg Pathol 26 (2002) 1259-1268
3. Fischer M., Wohlrab J., Audring T.H., Sterry W., and Marsch W.C. Granulomatous mycosis fungoides: report of two cases and review of the literature. J Eur Acad Dermatol Venerol 14 (2000) 196-202
4. Willemze R., Jaffe E.S., Burg G., Cerroni L., Berti E., Swerdlow S.H., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105 (2005) 3768-3785
5. Ruiz-de-Casas A., Carrizosa-Esquivel A., Herrera-Saval A., Rios-Martin J.J., and Camacho F. Sezary syndrome associated with granulomatous lesions during treatment with bexarotene. Br J Dermatol 154 (2006) 372-374
6. Vergier B., de Muret A., Beylot-Barry M., Vaillant L., Ekouevi D., Chene G., et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. Blood 95 (2000) 2212-2218
7. Imashuku S. Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment. Int J Hematol 66 (1997) 135-151
8. Henter J.I., and Elinder G. Ost A, and the FHL Study Group of the Histiocyte Society. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. Semin Oncol 18 (1991) 29-33
9. Duvic M., Feasel A.M., Schwartz C.A., and Cather J.C. Enterococcal eschars in cutaneous T-cell lymphoma tumors: a distinct clinical entity. Clin Lymphoma 2 (2000) 141-145
10. Zhang C., Hazarika P., Ni X., Weidner D.A., and Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 8 (2002) 1234-1240
11. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109 (2007) 31-39
12. Zhang C., Richon V., Ni X., Talpur R., and Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125 (2005) 1045-1052
13. Altucci L., and Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 1 (2001) 183-191
14. Sebestjen M., Keber I., Zegura B., Simcic S., Bozic M., Fressart M.M., et al. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thromb Haemost 92 (2004) 1129-1135
15. Crowe D.L., and Chandraratna R.A. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Cancer Res 6 (2004) 546-555